CLINICAL TRIALS PROFILE FOR EPTIFIBATIDE
✉ Email this page to a colleague
All Clinical Trials for eptifibatide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00061373 ↗ | Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST) | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | 2003-05-01 | Ischemic stroke is caused by a blood clot that blocks the flow of blood to the brain and damages brain cells. The clot, or thrombus, is made up of platelets and fibrin. The medicine alteplase, also known as tPA , is the standard drug used to treat patients with acute ischemic stroke. tPA attacks the fibrin portion of the blood clot. While intravenous (iv) tPA alone is effective in treating the fibrin part of the clot approximately 30% of the time, adding other commercially available drugs such eptifibatide to treat other clot components may improve the effectiveness of iv tPA therapy. This is a clinical trial to determine an acceptable dose of eptifibatide in combination with aspirin, the low molecular weight heparin tinzaparin, and standard iv tPA therapy for the treatment of acute ischemic stroke. Use of clinical and imaging based selection criteria are hypothesized to contribute to treatment safety by selecting patients at lower risk of intracerebral hemorrhage. Also,selection and evaluation of patients by magnetic resonance imaging (MRI) criteria will result in a different risk to benefit ratio than selecting patients without MRI criteria and will lead to a different acceptable dose. |
| NCT00089895 ↗ | EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) | Completed | Duke Clinical Research Institute | Phase 3 | 2004-11-01 | The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed provisional use of eptifibatide). |
| NCT00089895 ↗ | EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-11-01 | The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed provisional use of eptifibatide). |
| NCT00111566 ↗ | BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention | Completed | University of British Columbia | Phase 4 | 2004-12-01 | This trial was designed to examine the efficacy of a brief versus a standard prolonged (18 hours) infusion of eptifibatide in preventing troponin I release following successful coronary stenting. |
| NCT00111566 ↗ | BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention | Completed | Cardiology Research UBC | Phase 4 | 2004-12-01 | This trial was designed to examine the efficacy of a brief versus a standard prolonged (18 hours) infusion of eptifibatide in preventing troponin I release following successful coronary stenting. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for eptifibatide
Condition Name
Clinical Trial Locations for eptifibatide
Trials by Country
Clinical Trial Progress for eptifibatide
Clinical Trial Phase
Clinical Trial Sponsors for eptifibatide
Sponsor Name
